Burning rock secures second ngs kit approval from the nmpa

Guangzhou, china, march 15, 2022 (globe newswire) -- burning rock biotech limited (nasdaq: bnr, the “company” or “burning rock”) today announced that the national medical products administration (nmpa) approved burning rock's human nine-gene mutation joint detection kit (reversible termination sequencing) (lungcure™ cdx) as a class iii medical device. this approval demonstrates burning rock's industry-leading capability of working with the nmpa on bringing an innovative next generation sequencing (ngs)-based diagnostic product to the china market.
BNR Ratings Summary
BNR Quant Ranking